Xeris Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$10.1M
Doctors Paid
30,905
Transactions
98,367
2024 Total
$1.7M
Payment Breakdown by Category
Research$6.3M (62.0%)
Food & Beverage$2.0M (19.8%)
Consulting$488,621 (4.8%)
Travel$148,228 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.3M | 263 | 62.0% |
| Food and Beverage | $2.0M | 95,817 | 19.8% |
| Honoraria | $848,286 | 460 | 8.4% |
| Consulting Fee | $488,621 | 247 | 4.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $228,056 | 122 | 2.3% |
| Travel and Lodging | $148,228 | 627 | 1.5% |
| Education | $103,193 | 829 | 1.0% |
| Grant | $17,000 | 2 | 0.2% |
Payments by Type
Research
$6.3M
263 transactions
General
$3.8M
98,104 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| XP-8121-108 | $3.1M | 0 | 20 |
| XP-8121-120 | $1.3M | 0 | 58 |
| XP-9164-109 | $711,566 | 0 | 7 |
| COR-2017-OLE | $312,787 | 1 | 88 |
| GLUCAGON INFUSION IN T1D PATIENTS WITH RECURRENT SEVERE HYPOGLYCEMIA: EFFECTS ON COUNTER-REGULATORY RESPONSES | $253,965 | 0 | 7 |
| A PHASE 1, OPEN-LABEL, SINGLE-ARM, THREE-TREATMENT, THREE-WAY, CROSSOVER PHARMACOKINETICS STUDY OF XP-0863 IN HEALTHY SUBJECTS | $224,374 | 0 | 1 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL FOLLOWING OPEN LABEL THERAPY STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEVOKETOCONAZOLE (2S, 4R-KETOCONAZOLE) IN THE TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME | $140,066 | 0 | 29 |
| PHASE 2, RANDOMIZED, OPEN-LABEL, CROSSOVER, PD/PK STUDY OF A NOVEL PRAM-INSULIN CO-FORMULATION IN ADULTS WITH T1D | $75,427 | 0 | 10 |
| AN OPEN-LABEL EXTENSION STUDY OF LEVOKETOCONAZOLE (2S,4R-KETOCONAZOLE) IN THE TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME | $70,251 | 0 | 24 |
| HEED the Glucagon Access Program (HEED the GAP) | $53,000 | 0 | 1 |
| GLUCAGON READY TO USE (RTU) IN SUBJECTS WITH HYPERINSULINEMIC HYPOGLYCEMIA AFTER BARIATRIC SURGERY | $42,766 | 0 | 11 |
| COR-2017-01 | $9,429 | 0 | 7 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Jeffrey Sherman, M.d, M.D | Infectious Disease | Deerfield, IL | $291,087 | $0 |
| Mrs. Jessica Adkins, Dnp, Cpnp-Pc, DNP, CPNP-PC | Pediatrics | Savannah, GA | $142,346 | $0 |
| Bruce Bode, M.d, M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $89,482 | $0 |
| Elena Christofides, Md, Face, MD, FACE | Endocrinology, Diabetes & Metabolism | Columbus, OH | $76,490 | $0 |
| Philip Rabito, M.d, M.D | Specialist | New York, NY | $74,233 | $0 |
| Bantwal Baliga, Md,Dgo, MD,DGO | Family Medicine | Columbus, GA | $63,491 | $0 |
| John Paes, Do, DO | Endocrinology, Diabetes & Metabolism | Westerville, OH | $38,723 | $0 |
| Terrence Swade, M.d, M.D | Endocrinology, Diabetes & Metabolism | Lombard, IL | $38,429 | $0 |
| Nicholas Argento, M.d.l, M.D.L | Endocrinology, Diabetes & Metabolism | Laurel, MD | $33,713 | $0 |
| Dr. David Kayne, M.d, M.D | Specialist | Encino, CA | $31,650 | $0 |
| Dr. Steven Edelman, M.d, M.D | Internal Medicine | San Diego, CA | $31,277 | $0 |
| Dr. Shawn Peavie, D.o, D.O | Endocrinology, Diabetes & Metabolism | Cincinnati, OH | $31,165 | $0 |
| Dr. Michael Shanik, M.d, M.D | Endocrinology, Diabetes & Metabolism | Smithtown, NY | $30,234 | $0 |
| Robert Zimmerman, Md, MD | Endocrinology, Diabetes & Metabolism | Cleveland, OH | $28,232 | $0 |
| Arelis Madera, Md, MD | Endocrinology, Diabetes & Metabolism | Port Charlotte, FL | $27,975 | $0 |
| Lee Metchick, Md, MD | Endocrinology, Diabetes & Metabolism | Deland, FL | $26,853 | $0 |
| Firas Akhrass, Md, MD | Endocrinology, Diabetes & Metabolism | San Antonio, TX | $24,431 | $0 |
| Dr. David Ahn, Md, MD | Endocrinology, Diabetes & Metabolism | Newport Beach, CA | $24,204 | $0 |
| Dr. Benjamin Brannick, Md, MD | Student in an Organized Health Care Education/Training Program | Memphis, TN | $23,826 | $0 |
| Mark Vanderwel, Md, MD | Pediatrics | Charlotte, NC | $19,813 | $0 |
| Lisa Coco, N.p, N.P | Nurse Practitioner | Philadelphia, PA | $19,345 | $0 |
| Ilja Hulinsky, Md Phd, MD PHD | Endocrinology, Diabetes & Metabolism | West Haven, CT | $18,444 | $0 |
| Dr. Shimon Harary, Md, MD | Endocrinology, Diabetes & Metabolism | Memphis, TN | $18,321 | $0 |
| Gloria Ortiz, M.d, M.D | Endocrinology, Diabetes & Metabolism | Mcallen, TX | $18,146 | $0 |
| Dr. Zaid Jabbar, M.d, M.D | Internal Medicine | Oak Brook, IL | $17,800 | $0 |
Ad
Top Products
- GVOKE PFS $1.9M
- GVOKE HYPOPEN $1.5M
Associated Products (3)
- GVOKE PFS $1.9M
- GVOKE HYPOPEN $1.5M
- RECORLEV $892,493
Payment Categories
- Food & Beverage $2.0M
- Consulting $488,621
- Travel & Lodging $148,228
- Research $6.3M
About Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. has made $10.1M in payments to 30,905 healthcare providers, recorded across 98,367 transactions in the CMS Open Payments database. In 2024, the company paid $1.7M. The top product by payment volume is GVOKE PFS ($1.9M).
Payments were distributed across 224 medical specialties. The top specialty by payment amount is Endocrinology, Diabetes & Metabolism ($1.2M to 2,308 doctors).
Payment categories include: Food & Beverage ($2.0M), Consulting ($488,621), Research ($6.3M), Travel & Lodging ($148,228).
Xeris Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.